564 related articles for article (PubMed ID: 16144528)
61. Technology evaluation: APC-8015, Dendreon.
Rini BI
Curr Opin Mol Ther; 2002 Feb; 4(1):76-9. PubMed ID: 11883698
[TBL] [Abstract][Full Text] [Related]
62. Classification of the bladder cancer patient based on in vitro measurements of the immune response.
Lange PH; Hakala TR; Fraley EE
Cancer Res; 1977 Aug; 37(8 Pt 2):2885-90. PubMed ID: 326395
[TBL] [Abstract][Full Text] [Related]
63. [Immunotherapy of cancer: promise and reality].
Chouaib S; El Hage F; Benlalam H; Mami-Chouaib F
Med Sci (Paris); 2006; 22(8-9):755-9. PubMed ID: 16962052
[TBL] [Abstract][Full Text] [Related]
64. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
65. [State of the art about new therapeutic vaccines in prostate cancer: dendritic cells, engineered tumor cells and recombinant virus].
Eymard JC; Gervais A; Jarcau R; Bernard J
Bull Cancer; 2007 Jul; 94(7 Suppl):F69-76. PubMed ID: 17845996
[TBL] [Abstract][Full Text] [Related]
66. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
67. Dendritic cell-based vaccination against cancer.
Saito H; Frleta D; Dubsky P; Palucka AK
Hematol Oncol Clin North Am; 2006 Jun; 20(3):689-710. PubMed ID: 16762730
[TBL] [Abstract][Full Text] [Related]
68. Preliminary evidence that the allogeneic response might trigger antitumour immunity in patients with advanced prostate cancer.
Muir G; Rajbabu K; Callen C; Fabre JW
BJU Int; 2006 Nov; 98(5):989-95. PubMed ID: 16879440
[TBL] [Abstract][Full Text] [Related]
69. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
[TBL] [Abstract][Full Text] [Related]
70. Immunosuppressive networks in the tumour environment and their therapeutic relevance.
Zou W
Nat Rev Cancer; 2005 Apr; 5(4):263-74. PubMed ID: 15776005
[TBL] [Abstract][Full Text] [Related]
71. DNA vaccines for the treatment of prostate cancer.
Alam S; McNeel DG
Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
[TBL] [Abstract][Full Text] [Related]
72. Tumor immunotherapy: inching toward the finish line.
Curiel TJ; Curiel DT
J Clin Invest; 2002 Feb; 109(3):311-2. PubMed ID: 11827989
[No Abstract] [Full Text] [Related]
73. [Cellular immunotherapy: complexity of immune system and industrial development].
Abastado JP
Bull Cancer; 2003; 90(8-9):789-94. PubMed ID: 14609770
[TBL] [Abstract][Full Text] [Related]
74. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
[TBL] [Abstract][Full Text] [Related]
75. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
76. Standard treatments induce antigen-specific immune responses in prostate cancer.
Nesslinger NJ; Sahota RA; Stone B; Johnson K; Chima N; King C; Rasmussen D; Bishop D; Rennie PS; Gleave M; Blood P; Pai H; Ludgate C; Nelson BH
Clin Cancer Res; 2007 Mar; 13(5):1493-502. PubMed ID: 17332294
[TBL] [Abstract][Full Text] [Related]
77. Immunologic approaches to the treatment of prostate cancer.
Harris DT; Matyas GR; Gomella LG; Talor E; Winship MD; Spitler LE; Mastrangelo MJ
Semin Oncol; 1999 Aug; 26(4):439-47. PubMed ID: 10482186
[TBL] [Abstract][Full Text] [Related]
78. Tumour immunotherapy: the adjuvant treatment of the 21st century?
Bremers AJ; Kuppen PJ; Parmiani G
Eur J Surg Oncol; 2000 Jun; 26(4):418-24. PubMed ID: 10873365
[TBL] [Abstract][Full Text] [Related]
79. Immunotherapy in multiple myeloma--possibility or probability?
Harrison SJ; Cook G
Br J Haematol; 2005 Aug; 130(3):344-62. PubMed ID: 16042684
[TBL] [Abstract][Full Text] [Related]
80. Immune monitoring of cancer patients undergoing experimental immunotherapy.
Shankar G; Salgaller ML
Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
